How to Help Your Patients Find Ogsiveo in Stock: A Provider's Guide

When you prescribe Ogsiveo (nirogacestat) to a desmoid tumor patient, the prescription is just the beginning. Getting that medication into your patient's hands requires navigating a specialty pharmacy ecosystem, insurance prior authorization, and a series of logistical steps that can take days or weeks if not actively managed. Patients who aren't prepared for this process can experience dangerous gaps in therapy — and many don't know who to call when things stall.

This guide gives you and your care team a practical framework for helping patients access Ogsiveo as efficiently as possible — from the moment of prescribing through long-term refill management.

Step 1: Enroll the Patient in SpringWorks CareConnections at the Time of Prescribing

Don't wait until a problem arises to enroll. CareConnections should be initiated the same day you prescribe Ogsiveo. The enrollment form is available at springworkstxcares.com or by calling 1-844-CARES-55. Once enrolled, a dedicated nurse advocate is assigned to the patient and takes over insurance navigation, benefits verification, and specialty pharmacy coordination.

Key points to communicate to the patient:

The specialty pharmacy may call from an unfamiliar number — advise them to answer

Processing the prescription may take 1–3 weeks on the first fill due to prior authorization

If commercially insured, they may be eligible for $0 copay — they should ask CareConnections to enroll them

Step 2: Submit a Complete Prior Authorization Package

The most common reason for PA delays is incomplete documentation. Submit the following proactively to avoid back-and-forth with the insurer:

Pathology report confirming desmoid tumor diagnosis (image-guided core needle biopsy or surgical biopsy)

Imaging reports (CT or MRI) documenting tumor progression within the prior 12 months

Clinical notes documenting symptoms (pain levels, functional impairment) or potential for morbidity

Prescribing oncologist's NPI and attestation of specialist involvement

NCCN Category 1 guideline citation for nirogacestat in desmoid tumors (for use in appeal letters if needed)

CareConnections nurse advocates can assist with PA submission and appeal management — but your office needs to ensure the clinical documentation is accurate and complete.

Step 3: Verify Correct Tablet Strengths in Your Prescription

As of January 2025, the 50 mg Ogsiveo tablet is no longer available. The current FDA-approved tablet strengths are:

150 mg tablet — for standard dosing of 150 mg twice daily

100 mg tablet — for dose-reduced patients (100 mg twice daily)

Update your EHR prescribing templates and ensure any orders written for 50 mg tablets are corrected. Prescriptions for discontinued strengths will be rejected by the specialty pharmacy, causing delays.

Step 4: Direct the Prescription to the Correct Specialty Pharmacy

Ogsiveo cannot be dispensed at retail pharmacies. Before sending the prescription, confirm which specialty pharmacy is in-network for your patient's insurance plan. Sending to the wrong pharmacy — even an in-network specialty pharmacy that is not the plan's preferred partner — can result in a claim denial and significant delay.

If you're unsure which pharmacy is covered, CareConnections or a benefits specialist can verify this before the prescription is submitted.

Step 5: Use Bridge Programs for Time-Sensitive Cases

For patients who need to start Ogsiveo urgently but are waiting on insurance approval, two bridge programs are available:

Quick Start Program: Provides an initial 30-day supply plus one refill for eligible commercially insured patients whose insurance decision is pending.

Gap Coverage Program: Provides an initial 30-day supply plus up to two refills for eligible patients experiencing a lapse in insurance coverage.

These programs require enrollment through CareConnections and have specific eligibility criteria. Initiating the enrollment conversation early — before a coverage gap occurs — gives patients the best chance of seamless access.

Step 6: Proactively Manage Ongoing Refills

Ongoing therapy with Ogsiveo requires regular monitoring (liver function, electrolytes, skin surveillance) and timely refills. Advise your patients to:

Request refills 7–10 days before running out — specialty pharmacy processing is not same-day

Reconfirm insurance PA at the start of each calendar year — PAs often expire annually

Keep your oncologist's office updated on any insurance changes that could affect specialty pharmacy routing

How medfinder Can Support Your Patients

If a patient is having difficulty confirming which specialty pharmacy has Ogsiveo in stock, medfinder is a paid service that calls pharmacies on the patient's behalf and texts results of which ones can fill the prescription. This can cut hours off the search process. For more on the prescriber's role in managing Ogsiveo access, see our article on what providers need to know about Ogsiveo access in 2026.